Strategies for the identification of allosteric modulators of G-protein-coupled receptors

Biochemical Pharmacology

Volumn 81, Issue 6, 2011, Pages 691-702

  Burford, Neil T ^a   Watson, John ^a   Bertekap, Robert ^a   Alt, Andrew ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Allosteric modulators; Ca2+ signaling; G protein coupled receptors; High throughput screening

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; AMILORIDE DERIVATIVE; ANTALARMIN; CHEMOKINE RECEPTOR CCR5; CINACALCET; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 100; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; OLCEGEPANT; QUINOXALINE DERIVATIVE; RANTES; REPARIXIN; TRICHOSANTHIN;

ALLOSTERISM; BINDING SITE; HIGH THROUGHPUT SCREENING; NOTE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79951958713     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.12.012     Document Type: Note

References (107)

1. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006;1:761-82.
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6.
3. Premont RT, Gainetdinov RR. Physiological roles of G-protein-coupled receptor kinases and arrestins. Annu Rev Physiol 2007;69:511-34. (Pubitemid 46457653)
4. Kenakin T. Agonist-specific receptor conformations. Trends Pharmacol Sci 1997;18:416-7. (Pubitemid 27521058)
5. Changeux JP. Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol 2010;50:1-38.
6. Bridges TM, Lindsley CW. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 2008;3:530-41.
7. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54.
8. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2007;28:382-9. (Pubitemid 47087967)
9. De Amici M, Dallanoce C, Holzgrabe U, Trankle C, Mohr K. Allosteric ligands for G-protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 2009;30:463-549.
10. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003;63: 1256-72.
11. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, et al. Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 2001; 40:976-83. (Pubitemid 32530603)
12. Partin KM, Patneau DK, Mayer ML. Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. Mol Pharmacol 1994;46:129-38.
13. Johansen TH, Chaudhary A, Verdoorn TA. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol 1995;48:946-55.
14. Schwartz TW, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 2006;26:107-28.
15. Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:939-49.
16. Schwartz TW, Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 2007;28:366-73.
17. Nawaratne V, Leach K, Felder CC, Sexton PM, Christopoulos A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 2010;285:19012-21.
18. Raddatz R, Schaffhauser H, Marino MJ. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment. Biochem Pharmacol 2007;74:383-91. (Pubitemid 46963242)
19. Kenakin T, Principles. Receptor theory in pharmacology. Trends Pharmacol Sci 2004;25:186-92.
20. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997;52:172-9. (Pubitemid 27318633)
21. Kenakin TP. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009;30:460-9.
22. Gasparini F, Kuhn R, Pin JP. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2002;2:43-9.
23. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 2007;104:937-42. (Pubitemid 46154715)
24. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 2005; 68:1793-802. (Pubitemid 41654362)
25. Carter NJ, Keating GM. Maraviroc. Drugs 2007;67:2277-88 [discussion 89-90].
26. Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother 2009;10:2445-66.
27. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem 2004;279:7254-63. (Pubitemid 38248875)
28. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998;95:4040-5. (Pubitemid 28173250)
29. Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 2008;4:1551-60.
30. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983;220:141-62. (Pubitemid 14217337)
31. Thomsen W, Frazer J, Unett D. Functional assays for screening GPCR targets. Curr Opin Biotechnol 2005;16:655-65. (Pubitemid 41654645)
32. Gilchrist 2nd MA, Cacace A, Harden DG. Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening. J Biomol Screen 2008;13: 486-93. (Pubitemid 351905080)
33. Kostenis E, Waelbroeck M, Milligan G. Techniques: Promiscuous G[alpha] proteins in basic research and drug discovery. Trends Pharmacol Sci 2005;26:595-602. (Pubitemid 41505228)
34. Yu R, Hinkle PM. Desensitization of thyrotropin-releasing hormone receptor-mediated responses involves multiple steps. J Biol Chem 1997;272:28301-7. (Pubitemid 27517773)
35. Lutjens R. Constructing tools to tackle allosteric modulation: specificity and challenges of an allosteric approach. Philadelphia, PA, USA: Allosteric and Orthosteric Modulator Congress; 2010.
36. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 2008;283:5669-76.
37. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci 1995;16:256-8.
38. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 2003;100:10782-7. (Pubitemid 37140105)
39. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci U S A 2003;100:11406-11. (Pubitemid 37205948)
40. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007;72:1393-401.
41. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner; implications for drug screening. Mol Pharmacol 2010;78:456-65.
42. Li J-W, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009;325:161-5.
43. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, Frelin C, et al. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 2000;57:797-804. (Pubitemid 30183722)
44. Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci U S A 1997;94:14115-9. (Pubitemid 28009719)
45. Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 2006;372:354-61.
46. Sela I, Golan G, Strajbl M, Rivenzon-Segal D, Bar-Haim S, Bloch I, et al. G protein coupled receptors-in silico drug discovery and design. Curr Top Med Chem 2010;10:638-56.
47. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
48. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, et al. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol 2010;77: 459-68.
49. Moller C, Slack M. Impact of new technologies for cellular screening along the drug value chain. Drug Discov Today 2010;15:384-90.
50. Haasen D, Schnapp A, Valler MJ, Heilker R, James I. G-Protein-coupled receptor internalization assays in the high-content screening format. Methods Enzymol 2006;414:121-39. (Pubitemid 44716220)
51. Davis C, Bradley S, Schiffer H, Friberg M, Koch K, Tolf B-R, et al. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. BMC Pharmacol 2009;9:14.
52. Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, Hanson BJ, et al. Differential effects of allosteric M1 muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor down-regulation. ACS Chem Neurosci 2010;1:542-51.
53. Soleilhac E, Nadon R, Lafanechere L. High-content screening for the discovery of pharmacological compounds: advantages, challenges and potential benefits of recent technological developments. Expert Opin Drug Discov 2010;5:135-44.
54. Verdonk E, Johnson K, McGuinness R, Leung G, Chen YW, Tang HR, et al. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev Technol 2006;4:609-19. (Pubitemid 46017404)
55. McGuinness R. Impedance-based cellular assay technologies: recent advances, future promise. Curr Opin Pharmacol 2007;7:535-40. (Pubitemid 47560223)
56. Fang Y, Frutos AG, Verklereen R. Label-free cell-based assays for GPCR screening. Comb Chem High Throughput Screening 2008;11:357-69. (Pubitemid 351830306)
57. Sturchler E. Characterization of GABA-B receptor allosteric modulators using the CellKey® system. In: Benefits of Label-Free Impedance Analysis for Complex GPCR Biology. San Francisco: MDS Sciex; 2010 , https://danaher. webex.com/ec0600l/eventcenter/recording/recordAction.do?siteurl=danaher &theAction=poprecord&path=pop-program-info&recordID=44910047.
58. Kent T, McAlpine C, Sabetnia S, Presland J. G-protein-coupled receptor heterodimerization: assay technologies to clinical significance. Curr Opin Drug Discov Dev 2007;10:580-9. (Pubitemid 47367773)
59. Milligan G. G-protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 2009;158:5-14.
60. Carron C, Pascal A, Djiane A, Boucaut J-C, Shi D-L, Umbhauer M. Frizzled receptor dimerization is sufficient to activate the Wnt/β-catenin pathway. J Cell Sci 2003;116:2541-50. (Pubitemid 36790135)
61. Davies JQ, Chang G-W, Yona S, Gordon S, Stacey M, Lin H-H. The role of receptor oligomerization in modulating the expression and function of leukocyte adhesion-G-protein-coupled receptors. J Biol Chem 2007;282: 27343-5.
62. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lanca AJ, et al. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 2004;279:35671-8. (Pubitemid 39100570)
63. Smith NJ, Milligan G. Allostery at G-protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev 2010; 62:701-25.
64. del Burgo LS, Milligan G. Heterodimerisation of G-protein-coupled receptors: implications for drug design and ligand screening. Expert Opin Drug Discov 2010;5:461-74.
65. Valant C, Sexton PM, Christopoulos A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv 2009;9:125-35.
66. Mohr K, Trankle C, Kostenis E, Barocelli E, De Amici M, Holzgrabe U. Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010;159:997-1008.
67. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, et al. A novel mechanism of G-protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 2008;283:29312-21.
68. Griffin MT, Figueroa KW, Liller S, Ehlert FJ. Estimation of agonist activity at G-protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther 2007;321:1193-207. (Pubitemid 46762694)
69. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G-protein-coupled receptor. Science 2007;318:1258-65. (Pubitemid 350172884)
70. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008;454:486-91.
71. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008;322:1211-7.
72. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008;454:183-7. (Pubitemid 351969893)
73. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: a G-protein-coupled receptor. Science 2000; 289:739-45. (Pubitemid 30650186)
74. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010;330:1066-71.
75. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010;330:1091-5.
76. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010;28:63-70.
77. Gao ZG, Kim SK, Ijzerman AP, Jacobson KA. Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 2005;5:545-53. (Pubitemid 40754168)
78. Howard MJ, Hughes RJ, Motulsky HJ, Mullen MD, Insel PA. Interactions of amiloride with alpha- and beta-adrenergic receptors: amiloride reveals an allosteric site on alpha 2-adrenergic receptors. Mol Pharmacol 1987;32: 53-8. (Pubitemid 17112315)
79. Waugh DJ, Gaivin RJ, Damron DS, Murray PA, Perez DM. Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation. J Pharmacol Exp Ther 1999;291:1164-71.
80. Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, Croker DE, et al. Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem 2003;278:34451-7. (Pubitemid 37553292)
81. Swaminath G, Steenhuis J, Kobilka B, Lee TW. Allosteric modulation of beta2-adrenergic receptor by Zn(2+). Mol Pharmacol 2002;61:65-72.
82. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M. Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 2008;29:280-6.
83. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG, et al. Identification of allosteric peptide agonists of CXCR4. J Biol Chem 2003;278:896-907. (Pubitemid 36790764)
84. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000;275:25985-92.
85. Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 2008;381:956-74.
86. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005;67:1268-82. (Pubitemid 40410427)
87. Schetz JA, Sibley DR. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. J Neurochem 1997;68:1990-7. (Pubitemid 27176135)
88. Schetz JA, Sibley DR. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J Pharmacol Exp Ther 2001;296:359-63. (Pubitemid 32112461)
89. Schetz JA. Allosteric modulation of dopamine receptors. Mini Rev Med Chem 2005;5:555-61. (Pubitemid 40754169)
90. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, Skoblenick K, et al. Modulation of agonist binding to human dopamine receptor subtypes by Lprolyl-L-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 2005;315:1228-36. (Pubitemid 41635411)
91. Hoare SR, Coldwell MC, Armstrong D, Strange PG. Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol 2000;130:1045-59.
92. Arey BJ. Allosteric modulators of glycoprotein hormone receptors: discovery and therapeutic potential. Endocrine 2008;34:1-10.
93. Waelbroeck M. Allosteric drugs acting at muscarinic acetylcholine receptors. Neurochem Res 2003;28:419-22. (Pubitemid 36314827)
94. Birdsall NJ, Lazareno S. Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 2005;5:523-43. (Pubitemid 40754167)
95. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009;30:148-55.
96. Im WB, Chio CL, Alberts GL, Dinh DM. Positive allosteric modulator of the human 5-HT2C receptor. Mol Pharmacol 2003;64:78-84. (Pubitemid 36759820)
97. Hoare SR. Allosteric modulators of class B G-protein-coupled receptors. Curr Neuropharmacol 2007;5:168-79. (Pubitemid 351863858)
98. Sheykhzade M, Lind H, Edvinsson L. Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries. Br J Pharmacol 2004;143:1066-73. (Pubitemid 40065508)
99. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109:339-65. (Pubitemid 43132817)
100. Urwyler S, Gjoni T, Koljatic J, Dupuis DS. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 2005;48:343-53. (Pubitemid 40249997)
101. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2- dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001;60:963-71. (Pubitemid 33027431)
102. Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem Soc Trans 2004;32:881-7. (Pubitemid 39524404)
103. Marino MJ, Conn PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 2006;6:98-102. (Pubitemid 43103825)
104. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 2004;309:568-77. (Pubitemid 38542609)
105. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005;313:199-206. (Pubitemid 40411343)
106. Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, et al. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A 2005;102:18712-7. (Pubitemid 43011291)
107. Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, et al. Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res 2010;212:168-73.